On January 12, the Food and Drug Administration approved the first treatment for breast cancer patients who have inherited mutations in their BRCA genes. By zeroing in on these mutations, the drug can help improve the quality and length of life for patients whose disease has metastasized, or spread throughout the body.
Read at: Genome Magazine